Loading...
•
Jun 30
Halozyme Q2 2025 Earnings Report
Halozyme reported strong second quarter 2025 results, with significant increases in total revenue, royalty revenue, net income, and EPS, leading to raised full-year financial guidance.
Key Takeaways
Halozyme delivered an exceptional second quarter in 2025, with total revenue surging by 41% year-over-year to $326 million, primarily fueled by a 65% increase in royalty revenue. Net income grew by 77% to $165 million, and GAAP diluted EPS rose by 85% to $1.33. The strong performance prompted the company to raise its full-year 2025 financial guidance for total revenue, adjusted EBITDA, and non-GAAP diluted EPS.
Total revenue increased 41% year-over-year to $325.7 million, driven by strong royalty and milestone revenue growth.
Royalty revenue significantly increased by 65% year-over-year to $205.6 million, primarily from DARZALEX SC, VYVGART Hytrulo, and Phesgo.
Net income rose 77% to $165.2 million, and GAAP diluted EPS increased 85% to $1.33.
Halozyme raised its full-year 2025 financial guidance for total revenue, adjusted EBITDA, and non-GAAP diluted EPS for the second time this year.
Halozyme
Halozyme
Halozyme Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.comProduct Sales, Net Revenue
CapyFin.comUnder Collaborative Agreements Revenue
CapyFin.com Forward Guidance
Halozyme has raised its full-year 2025 financial guidance, expecting total revenue between $1,275 million and $1,355 million, royalty revenue between $825 million and $860 million, adjusted EBITDA between $865 million and $915 million, and non-GAAP diluted EPS between $6.00 and $6.40.
Positive Outlook
- Total revenue guidance raised to $1,275 - $1,355 million, representing 26% - 33% year-over-year growth.
- Royalty revenue guidance raised to $825 - $860 million, representing 44% - 51% year-over-year growth.
- Adjusted EBITDA guidance raised to $865 - $915 million, representing 37% - 45% year-over-year growth.
- Non-GAAP diluted EPS guidance raised to $6.00 - $6.40, representing 42% - 51% year-over-year growth.
- Guidance reflects strong performance and growth trends, indicating confidence in continued business momentum.
Challenges Ahead
- The guidance reflects tariffs that are currently implemented, which could pose a risk if they change.
- The earnings per share guidance does not consider the impact of potential future share repurchases, which could affect EPS.
- The company does not provide reconciliations of forward-looking adjusted measures to GAAP, making it difficult to fully assess the GAAP impact.
- Forecasting and quantifying certain amounts for reconciliation are inherently difficult, leading to potential material differences between GAAP and Non-GAAP measures.
- The guidance is subject to various risks and uncertainties, including unexpected levels of revenues, expenditures, and costs, and regulatory changes.